ADVERTISEMENT
Reimbursement
The pharmaceutical industry has been pushing back on a deeply unpopular rebate on products deemed to be “free combination” medicines in Germany.
The pharmaceutical industry has been pushing back on a deeply unpopular rebate on products deemed to be “free combination” medicines in Germany.
As more medicines come off patent in the coming years, the UK generics and biosimilars industry association is hoping to see more generic products evaluated for reimbursement by the health technology assessment institute, NICE.
As more medicines come off patent in the coming years, the UK generics and biosimilars industry association is hoping to see more generic products evaluated for reimbursement by the health technology assessment institute, NICE.
The National Health Service said the roll out of ViiV Healthcare’s Apretude would bring England closer to its aim of becoming the first country in the world to end HIV transmissions by 2030.
Revision of the EU’s pharmaceutical legislation will include a new definition of unmet need, but getting it wrong could have unintended consequences for pricing and reimbursement.
Leaders from MSD, Immuneel Therapeutics and ICICI Lombard discuss the pathway and potential models to deliver a billion-dollar therapy in India.
Leaders from MSD, Immuneel Therapeutics and ICICI Lombard discuss the pathway and potential models to deliver a billion-dollar therapy in India.
The gap between investor returns and patient returns is precisely that which the SALY/SADY framework is designed to fill.
The latest report also demonstrates the EU’s trade relationships around the world, including with the US.
A July white paper from Lifescience Dynamics explores the potential ways AI could see usage in pricing, reimbursement and market access for biopharma companies.
Senior Indegene executive William Lobb talks about complexities of the direct-to-patient distribution model in the US, including potentially introducing new intermediaries into the system. Questions on MFN's feasibility and why it may be “catastrophic” to biopharma were also part of the discussion